Edition:
United States

Critical Outcome Technologies Inc (COT.V)

COT.V on TSX Venture Exchange

0.46CAD
2 Dec 2016
Change (% chg)

$-0.04 (-8.00%)
Prev Close
$0.50
Open
$0.49
Day's High
$0.49
Day's Low
$0.45
Volume
36,250
Avg. Vol
101,392
52-wk High
$0.90
52-wk Low
$0.21

COT.V

Chart for COT.V

About

Critical Outcome Technologies Inc. (COTI) is a clinical-stage biopharmaceutical company. The Company is engaged in drug discovery and development. The Company uses machine learning to develop targeted therapies thereby managing the timeline and cost of getting new drug therapies to market. The Company's artificial intelligence... (more)
No analyst recommendations are available for COT.V.

Overall

Beta: 0.20
Market Cap(Mil.): $80.38
Shares Outstanding(Mil.): 148.86
Dividend: --
Yield (%): --

Financials

  COT.V Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.05 -- --
ROI: -204.71 -1.09 14.95
ROE: -204.71 -2.39 16.29

BRIEF-Critical Outcome Technologies provides update on future strategic objectives

* Critical Outcome Technologies provides update on recent achievements and future strategic objectives at annual general meeting

Oct 14 2016

BRIEF-Critical Outcome appoints Bharatt Chowrira to its board

* Critical Outcome appoints Dr. Bharatt Chowrira to its board of directors Source text for Eikon: Further company coverage:

Sep 13 2016

BRIEF-Critical Outcome Technologies Q4 loss per share c$0.018

* Q4 loss per share c$0.018 Source text for Eikon: Further company coverage:

Aug 03 2016

BRIEF-Critical Outcome Tech appoints Alison Silva as new president

* Appointment of alison silva as new president of company effective july 5, 2016

Jun 15 2016

BRIEF-Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study

* Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 06 2016

Earnings vs. Estimates